Sign In
Buy AORT
$20.58
+0.160 (+0.784%)
At Close: Jun 03, 2026
Artivion to Participate in Upcoming Investor Conferences
04:15pm, Tuesday, 05'th Nov 2024
ATLANTA , Nov. 5, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2024 Financial Results
04:15pm, Thursday, 24'th Oct 2024
ATLANTA , Oct. 24, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2024 financial result
5-Year Data from the AMDS DARTS Trial Demonstrates Positive Aortic Remodeling with 94% of Patients Free from Unanticipated Reoperation 30-Day Data from the AMDS PERSEVERE Trial Shows Cerebral Malperfu
Artivion, Inc. (AORT) Q2 2024 Earnings Call Transcript
02:45pm, Saturday, 10'th Aug 2024
Artivion, Inc. (NYSE:AORT ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Eileen Martin - Investor Relations Pat Mackin - Chief Executive Officer Lance Berry - Chief
Artivion (AORT) Surpasses Q2 Earnings and Revenue Estimates
06:50pm, Thursday, 08'th Aug 2024
Artivion (AORT) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.06 per share a year ago.
Artivion Reports Second Quarter 2024 Financial Results
04:05pm, Thursday, 08'th Aug 2024
Second Quarter Highlights: Achieved revenue of $98.0 million in the second quarter of 2024 versus $89.3 million in the second quarter of 2023, an increase of 10% on both a GAAP and constant currency
Artivion to Participate in Upcoming Investor Conferences
04:10pm, Monday, 05'th Aug 2024
ATLANTA , Aug. 5, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming i
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2024 Financial Results
04:10pm, Thursday, 25'th Jul 2024
ATLANTA , July 25, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2024 financial resul
3 Earnings All-Stars With More Room to Run
08:00am, Wednesday, 03'rd Jul 2024
Earnings are essential to determining which stocks will outperform. Unsurprisingly, earnings outperformers also see strong price appreciation.
Artivion Amends Agreements with Endospan
04:05pm, Monday, 01'st Jul 2024
Provides Endospan with $25 million of Additional Debt Funding to Obtain FDA Approval for NEXUS Upfront Payment Associated with Purchase Option Reduced to $135 million, inclusive of loan off-set, and $
Data-Driven Growth Fuels More Upside For Overlooked Artivion
05:01pm, Friday, 21'st Jun 2024
Artivion, Inc. has continued to log double-digit revenue growth with contributions from diverse assets including its stent grafts, heart valves, and cryopreserved tissue grafts. Positive post-approval
Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue?
10:17am, Wednesday, 08'th May 2024
Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Artivion, Inc. (AORT) Q1 2024 Earnings Call Transcript
10:47pm, Monday, 06'th May 2024
Artivion, Inc. (NYSE:AORT ) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Eileen Martin - Investor Relations Pat Mackin - Chief Executive Officer Lance Berry - Chief Fin
Artivion (AORT) Tops Q1 Earnings and Revenue Estimates
06:21pm, Monday, 06'th May 2024
Artivion (AORT) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.02 per share a year ago.
Artivion Reports First Quarter 2024 Financial Results
04:05pm, Monday, 06'th May 2024
First Quarter Highlights: Achieved revenue of $97.4 million in the first quarter of 2024 versus $83.2 million in the first quarter of 2023, an increase of 17% on a GAAP basis and 16% on a non-GAAP con
